TIFA Antikörper (AA 51-150) (Biotin)

Produktnummer ABIN1700078

Produktdetails anti-TIFA Antikörper (Biotin)

Target: TIFA (TRAF-Interacting Protein with Forkhead-Associated Domain (TIFA))

Bindungsspezifität: AA 51-150

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser TIFA Antikörper ist konjugiert mit Biotin

Applikation: ELISA, Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Kreuzreaktivität: Maus

Homologie: Human,Rat,Dog,Cow,Sheep,Pig,Chicken

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human TIFA

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C for 12 months.

Haltbarkeit: 12 months

Details zu TIFA

Target: TIFA (TRAF-Interacting Protein with Forkhead-Associated Domain (TIFA))

Andere Bezeichnung: TIFA (TIFA Produkte)

Hintergrund:

Synonyms: Putative MAPK activating protein PM14, Putative MAPK-activating protein PM14, Putative NF kappa B activating protein 20, Putative NF-kappa-B-activating protein 20, T2BP, TA, TA_HUMAN, TRAF interacting protein with FHA domain containing protein A, TRAF-interacting protein with FHA domain-containing protein A, TRAF2 binding protein, TRAF2-binding protein.

Background: Adapter protein which mediates the IRAK1 and TRAF6 interaction following IL-1 stimulation, resulting in the downstream activation of NF-kappa-B and AP-1 pathways. Induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.